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Abstract
In the management of patients with lymphoma, imaging is essential not only for diagnosis but also to define prognosis
and treatment by staging. Imaging is also used to assess the response to treatment that may affect the treatment
strategy: new chemotherapeutic drug combinations and autologous stem cell transplantation. These different therapies
have increased the need for higher accuracy to assess the response to treatment. Standardised imaging response
criteria must be well known by radiologists involved in the management of patients with lymphoma. Criteria are
mainly volumetric, and are obtained from CT scans. Functional imaging techniques have been shown to provide
better information on the viability of residual masses than does CT assessment of size changes.
CT remains the main imaging technique to assess response to treatment based on volumetric international criteria. New
functional imaging tools evaluating perfusion (CT and MRI), and particularly glucose uptake (PET), will probably
play an important role in bringing additional information on the metabolism of lymphomatous masses.
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Introduction
Lymphomas encompass a spectrum of diseases among
which Hodgkin’s disease (HD) is distinct from non-
Hodgkin lymphomas (NHL). The pathological classifica-
tion of HD is well known. The nodular sclerosis subtype
is the most common, occurring in up to three-quarters
of all cases. The pathological classification of NHL
is more complex. The revised European and American
lymphoma (REAL) and World Health Organisation
(WHO) classifications are widely accepted [1,2]. The
histological subtypes include low, intermediate, and high-
grade NHL. Low-grade or so-called indolent NHL have a
prolonged clinical course but cure is usually not achieved
unless the disease is strictly localised. By contrast,
aggressive lymphoma, i.e. high and intermediate grade
NHL, is often a rapidly progressive disease characterised
by high proliferation rates. Treatment of aggressive NHL
with combination chemotherapy results in long-term cure
in a proportion of patients.
Prognostic indices have been devised with the aim
of identifying patients at risk of disease progression.
At diagnosis, three main factors have been shown to
adversely affect prognosis including the performance
status, the serum lactate deshydrogenase level, and
particularly the Ann Arbor stage reflecting the anatomic
extent of the disease [3]. A bulky mass, larger than
10 cm in diameter, may also confer an increased risk of
disease progression. These prognostic factors are useful
to ensure comparable patient groups among clinical trials
and acquisition of similar data. Using these factors, the
most appropriate therapeutic strategies can be applied for
each patient.
Imaging is, then, essential not only for diagnosis
but also to define prognosis and treatment by staging.
Imaging is also used to assess the response to treatment
that may affect the treatment strategy: new chemother-
apeutic drug combinations and autologous stem cell
transplantation. These different therapies have increased
the need for higher accuracy to assess the response to
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treatment [4]. Standardised imaging response criteria are,
then, essential when serial CT assessments are performed
during and after treatment [4]. These criteria must be well
known by radiologists involved in the management of
patients with lymphoma.
Radiological response to treatment
CT scans (thorax, abdomen, pelvis) remain the standard
for the volumetric evaluation of nodal disease even if
those areas were not initially involved because of the
unpredictable pattern of recurrence in NHL [4].
(i) Complete Response (CR) requires that (a) all
lymph nodes must have regressed to normal size
(<1.5 cm in their greatest diameter); (b) the spleen
must have regressed to normal size and (c) any
nodules in the spleen, liver or kidneys should no
longer be present.
(ii) CR/unconfirmed (CRu) requires a residual lymph
node mass greater than 1.5 cm in greatest
transverse diameter that has regressed by more
than 75% in the products of the greatest diameters
(perpendicular).
(iii) In partial response (PR) there must be (a) at least
a 50% decrease in the sum of the products of the
greatest diameters of the six largest nodal masses;
(b) a regression of at least 50% in the sum of the
products of the greatest diameters of splenic and
hepatic nodules; (c) no increase in the size of the
other nodes, liver or spleen and (d) no new sites of
disease.
(iv) Stable disease is defined as less than PR but is not
progressive disease
(v) Progressive disease (PR, non-responders) requires
(a) at least a 50% increase in the sum of the
products of the greatest diameters and (b) the
appearance of any new lesion.
(vi) Relapsed disease occurring after a CR or CRu
requires (a) at least a 50% increase in the sum of
the products of the greatest diameters (compared
to CR or CRu) and (b) the appearance of any new
lesion.
Radiological follow-up
The manner in which patients are observed after treat-
ment may differ between different centres and clinical
trials. A number of imaging studies are often performed
on a routine basis after every few courses of treatment and
every few months thereafter. After induction treatment,
CR and CRu must be differentiated from other situations
in order to adapt the therapeutic strategy. Therefore, CT
must always be performed during treatment, after the
induction phase and after the completion of treatment [4].
The timing of further follow-up imaging studies was a
topic of controversy when patients achieved CR or CRu.
Some studies assessed the role of imaging screening
for relapse. Only two of 36 relapses in aggressive NHL
were detected before symptoms were reported [5]. In
our institution, after complete remission is achieved, we
perform CT every six months during the first two years
and then every year for three years. Using this protocol,
CT diagnosed pre-clinical relapse in seven of 18 relapsing
patients with HD [6]. It is recommended that screening
studies should not be site-specific and that the frequency
of CT should be determined by the patient’s risk of
relapse and whether there is a potentially curative salvage
therapy. However, whether or not these conclusions are
relevant to patients with follicular lymphoma remains to
be studied.
Additional Studies for Evaluation
A number of additional imaging techniques have been
proposed to evaluate response to treatment. ‘Functional’
imaging techniques include CT measurement of per-
fusion, MR imaging, Gallium and more recently 18
fluorodeoxyglycose (18F-FDG) PET scan. All these
techniques have been shown to provide better information
on the viability of residual masses than does CT
assessment of size changes.
Lymph nodes
It is well known that tumours require a capillary
network to grow and survive. Ribatti et al. have
shown that the micro-vessel number was low in benign
lymphadenopathies, and increased in NHL [7]. Aggressive
NHL showed the highest count. With treatment of
lymphoma and cell death in the mass, there is induction
of inflammation, with subsequent fibrous tissue and
destruction of the existing capillary network. This
should be visible by a reduction in the perfusion and
permeability of the mass over time. Dugdale et al.
recently showed that perfusion measurements from
dynamic contrast-enhanced CT were higher in patients
with active residual masses and aggressive NHL [8].
Low perfusion measurements implied inactive disease.
CT perfusion measurements of nodes have potential
for assessing lymphoma grade, activity, and treatment
response.
The signal intensity of lymphoma in MR imaging
changes during the course of the disease. The theoretical
basis of signal changes is that (a) active, untreated tumour
tissue contains an excess of free water, increasing the
T2 signal intensity and (b) with successful treatment,
cellular elements and the water-content of the tumour
are reduced, while the collagen and fibrotic stroma of
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the original tumour become the main component of
the signal. These factors reduce the T2 signal intensity
of the residual mass. Active versus inactive residual
masses can be identified on the basis of signal intensity
patterns, as determined by optical reference to muscle
and fat on T1 and T2-weighted images. The sensitivity
of MR imaging for predicting relapse in a residual mass
ranges from 45% to 90% with a specificity of 80% to
90% in the different studies. Active tumour foci may
be found within a residual mass with a low T2 signal
intensity. Necrosis, immature fibrotic tissue, edema and
inflammation associated with responding disease can
simulate the high signal intensity of a viable tumour,
particularly within the first six months after therapy.
At diagnosis, gadolinium enhancement of lymphomatous
masses of the mediastinum is very different among
patients; it falls after treatment in patients in continuous
complete remission, but not in patients who relapse. MR
evaluation of residual lymphomatous masses requires a
pre-treatment baseline MR study for comparison, and can
be done not only with T2-weighted images but also with
gadolinium-enhanced sequences [9].
The mechanism of localisation of Gallium-67 citrate in
tumours is complex. Larson et al. propose a mechanism
in which the gallium ion after injection binds to
plasma transferrin and is then transported across the
cell membrane to the lysosomes [10]. Therefore several
local factors, such as vascularity and ion exchange
through membrane pores, can contribute to the uptake
of the gallium ion by the malignant cell. Gallium-67
scintigraphy has played an important role in monitoring
follow-up of patients; however the sensitivity of 67Ga
scintigraphy depends on the subtype of lymphoma and
the size and location of the disease. 67Ga scintigraphy
is valid for thoracic examination. No gallium uptake
can be seen in about 20% of lymphomatous masses at
diagnosis depending on tumour avidity and technique of
scanning [11,12]. The best results have been reported from
groups that used single-photon emission tomography
(SPECT). Studies comparing MR and gallium imaging
showed no superiority of the latter in predicting relapses.
Increased glycolysis, a biochemical feature of ma-
lignant cells, explains 18F-fluorodeoxyglucose (18F-
FDG) uptake by lymphomatous masses in positron
emission tomography (PET). This complex technique
offers at least equivalent results to CT for detecting
lymphoma during initial staging [13,14]. It may also iden-
tify patients requiring intensification after completion of
chemotherapy [15]. Promising results have also recently
been obtained in the detection of residual disease. False-
positive and rare false-negative cases have been reported.
The main advantage of PET is the imaging of almost the
entire body.
Bone marrow
Both MR imaging and 18F-FDG PET improve the
detection of bone marrow involvement. They can also
be used to assess the response to treatment, particularly
using dynamic gadolinium-enhanced MR imaging.
Conclusion
In conclusion, CT remains the main imaging technique
for assessing response to treatment based on volumetric
international criteria. New functional imaging tools
evaluating perfusion (CT and MRI) and particularly
glucose uptake (PET) will probably play an important
role in bringing additional information on the metabolism
of lymphomatous masses.
References
[1] Harris NL, Jaffe ES, Stein H et al. A revised European–
American classification of lymphoid neoplasms: a proposal from
the international Lymphoma Study Group. Blood 1994; 84:
1361–92.
[2] The International non-Hodgkin’s lymphoma prognostic factors
project. A predictive model for aggressive non-Hodgkin’s
lymphoma. N Engl J Med 1993; 329: 987–94.
[3] Hasenclever D. Diehl V for the international prognostic factors
project on advanced Hodgkin’s disease. A prognostic score for
advanced Hodgkin’s disease. N Engl J Med 1998; 339: 1506–14.
[4] Cheson BD, Horning SJ, Coiffier B et al. Report of an
international workshop to standardize response criteria for non-
Hodgkin’s lymphomas. J Clin Oncol 1999; 17: 1244–53.
[5] Weeks JC, Yeap BY, Canellos GP et al. Value of follow-up
procedures in patients with large-cell lymphoma who achieve a
complete remission. J Clin Oncol 1991; 9: 1196–203.
[6] Rahmouni A, Divine M, Lavaud A et al. Role of computed
tomography for the evolutive follow-up of Hodgkin’s disease. J
Radiol 1993; 74: 99–103.
[7] Ribatti D, Vacca A, Nico M, Fanelli M, Roncali L, Dammacco F.
Angiogenesis spectrum in the stroma of B-cell non-Hodgkin’s
lymphomas: an immunohistochemical and ultrastructural study.
Eur J Haematol 1996; 56: 45–53.
[8] Dugdale PE, Miles KA, Kelley BB, Leggett DA. CT measure-
ment of perfusion and permeability within lymphoma masses
and its ability to assess grade, activity and chemotherapeutic
response. J Comput Assist Tomogr 1999; 23: 540–7.
[9] Rahmouni A, Divine M, Lepage E et al. Quantitative MR
changes in gadolinium enhancement of mediastinal lymphoma
following treatment. Radiology 2001; 219: 621–8.
[10] Larson SM, Greenbaum Z, Rasey JS. The role of transferrins in
gallium uptake. Int J Nucl Med Biol 1981; 8: 257–66.
[11] Van Amsterdam JAG, Kluin-Nelemans JC, Van Eck-Smit BLF,
Pauwels EKJ. Role of 67Ga scintigraphy in localization of
lymphoma. Ann Hematol 1996; 72: 202–7.
[12] Coiffier B. Positron emission tomography and gallium metabolic
imaging in lymphoma. Cur Oncol Rep 2001; 3: 266–70.
[13] Moog F, Bangarter M, Diederichs CG et al. Lymphoma: role
of whole-body 2-deoxy-2-(F-18)-fluoro-D-glucose (FDG) PET
in nodal staging. Radiology 1997; 203: 795–800.
[14] Jerusalem G, Warland V, Najjar F, Paulus P, Fassotte MF,
Fillet G, Rigo P. Whole-body 18F-FDG PET for the evaluation of
patients with Hodgkin’s disease and non-Hodgkin’s lymphoma.
Nucl Med Commun 1999; 20: 13–20.
[15] Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P,
Fillet G. Whole-body positron emission tomography using 18F-
Fluorodeoxyglucose for post-treatment evaluation in Hodgkin’s
disease and non-Hodgkin’s lymphoma has higher diagnostic
and prognostic value than classical computed tomography scan
imaging. Blood 1999; 94: 429–33.
